Infusion of Donor Lymphocytes Depleted of CD25+ Regulatory T-cells in Patients With Relapsed Hematologic Malignancies

Sponsor

Dana-Farber Cancer Institute (Other)

Overall Status

Completed

CT.gov ID

NCT00675831

Collaborator

Miltenyi Biomedicine GmbH (Industry)

Enrollment

Location

Arm

Duration (Months)

0.4

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this research study is to evaluate the safety and efficacy of cell depletion in a donor lymphocyte infusion (DLI) product with the use of the CliniMACS machine. Previously, patients with hematologic malignancies who have relapsed after transplant have been given infusions of donor white blood cells calsed donor lymphocyte infusion (DLI) as a way to boost their immune function and fight cancer. Information from other research studies suggests that lowering the number of a certain type of white blood cell called CD25+ Tregs in the DLI may allow for a greater effect. In this research study, we are looking for the appropriate dose of DLI depleted of the CD25+ Treg white blood cells that can be given safely.

Condition or Disease	Intervention/Treatment	Phase
Hematologic Malignancies	Device: CliniMACS CD25 Reagent Device	Phase 1

Detailed Description

The original marrow/stem cell donor will undergo one or two white blood cell collection procedures called leukopheresis. The cells collected from the first leukopheresis will be sent to the laboratory where the amount of white blood cells collected will be measured. If the number of cells collected at the first leukopheresis is not enough, the donor will have a second leukopheresis procedure.
Once enough lymphocytes are collected from the donor, the CliniMACS CD25 Reagent System device will reduce the number of CD25+ Tregs. The CD25+ depleted donor lymphocytes will then be infused to the participant intravenously. Participants will be observed for about one hour after the infusion.
One, two, four and eight weeks after the DLI, participants will return to the clinic for follow-up visits. At each visit a physical exam, questions about the participants general health, and blood tests will be performed.

Study Design

Study Type:

Interventional

Actual Enrollment :

24 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Infusion of Donor Lymphocytes Depleted of CD25+ Regulatory T-cells in Patients With Relapsed Hematologic Malignancies After Matched Allogeneic Hematopoietic Stem Cell Transplantation

Study Start Date :

Dec 1, 2007

Actual Primary Completion Date :

Jan 1, 2013

Actual Study Completion Date :

Jan 1, 2013

Arms and Interventions

Arm	Intervention/Treatment
Experimental: CD25+ Treg depleted DLI dose schema Patients will receive a defined dose of CD25+ Treg depleted DLI. 5 patients will be enrolled, initially at dose level B, and subsequent cohorts will be dose adjusted per the CD3+ dose escalation/de-escalation schema: Dose level -C: 3x10^7 (CD3+Dose (#cells/kg)) Dose level -B: 1x10^7 (CD3+Dose (#cells/kg)) Dose level -A: 1x10^6 (CD3+Dose (#cells/kg)) Recipient's body weight in Kg	Device: CliniMACS CD25 Reagent Device Used to engineer CD25+ depleted donor lymphocytes which will be infused intravenously over 5-10 minutes

Arm

Intervention/Treatment

Experimental: CD25+ Treg depleted DLI dose schema

Patients will receive a defined dose of CD25+ Treg depleted DLI. 5 patients will be enrolled, initially at dose level B, and subsequent cohorts will be dose adjusted per the CD3+ dose escalation/de-escalation schema: Dose level -C: 3x10^7 (CD3+Dose (#cells/kg*)) Dose level -B: 1x10^7 (CD3+Dose (#cells/kg*)) Dose level -A: 1x10^6 (CD3+Dose (#cells/kg*)) *Recipient's body weight in Kg

Device: CliniMACS CD25 Reagent Device

Used to engineer CD25+ depleted donor lymphocytes which will be infused intravenously over 5-10 minutes

Outcome Measures

Primary Outcome Measures

To determine the feasibility of using the ClinMACS CD25 Reagent device to engineer a DLI product outlined in the protocol [3 years]
To determine the safety of CD25+ Treg depleted DLI in this patient population. [3 years]

Secondary Outcome Measures

To assess clinical response after infusions of CD25+ Treg depleted donor lymphocytes [3 years]
To assess the immunologic impact of infusions of CD25+ Treg depleted donor lymphocytes [3 years]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients with hematologic malignancies that have relapsed after HLA-A, -B, -C, and-DRBI matched allogeneic hematopoietic stem cell transplantation
At least 2 months following hematopoietic stem cell transplantation
Off any systemic immunosuppressive medication for treatment or prevention of GVHD, for a minimum of 2 weeks prior to study entry
Recipient with donor chimerism of 20% or greater within 6 weeks prior to DLI
Patient with less than 50% bone marrow involvement (% cellularity) and less than 5cm lymph nodes, in the 6 weeks prior to DLI
18 years of age or older
ECOG Performance Status score 0-2
Prior stem cell donor is medically fit to undergo leukapheresis procedure

Exclusion Criteria:

Relapsed CML in chronic phase
Prior donor lymphocyte infusion or other immunotherapy treatment within 8 weeks prior to enrollment
Chemotherapy within 4 weeks prior to enrollment
Clinically significant and active autoimmune disease in donor or patient. This is defined as autoimmune disease resulting in organ dysfunction and/or requiring systemic therapy
Evidence of active acute or chronic GVHD
Uncontrolled infection